Obesity may be erythropoietin dose-saving in hemodialysis patients-Reference-Cited by-同舟云学术

Obesity may be erythropoietin dose-saving in hemodialysis patients

Published:2018-06-30 Issue:2 Volume:37 Page:148-156
ISSN:2211-9140
Container-title:Kidney Research and Clinical Practice
language:en
Short-container-title:Kidney Res Clin Pract.

Author:

El-Kannishy Ghada M.¹^ORCID,Megahed Abir F.²,Tawfik Mona M.¹,El-Said Ghada¹,Zakaria Rabab T.³,Mohamed Nahed A.⁴,Taha Eman M.⁵,Ammar Alzhraa A.⁶,Abd Eltawab Abeer M.⁷,Sayed-Ahmed Nagy A.¹

Affiliation:

1. Mansoura Nephrology and Dialysis Unit (MNDU), Faculty of Medicine, Mansoura University, Mansoura, Egypt

2. Nephrology Unit, Mansoura Military Hospital, Mansoura, Egypt

3. El Minia Hemodialysis Center, El Minia, Egypt

4. Dialysis Unit, Abokeir Hospital, Alexandria, Egypt

5. Temy Alamdeed Dialysis Center, Dakahlyia, Egypt

6. Dialysis Unit, Alexandria Fever Hospital, Alexandria, Egypt

7. Dialysis Unit, Raas El Teen Hospital, Alexandria, Egypt

Publisher

The Korean Society of Nephrology

Subject

Urology,Nephrology

Link

http://pdf.medrang.co.kr/KRCP2/2018/037/KRCP037-02-08.pdf

Reference39 articles.

1. Survival advantages of obesity in dialysis patients

2. Obesity Paradox in End-Stage Kidney Disease Patients

3. Protein-Energy Wasting and Mortality in Chronic Kidney Disease

4. Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome)

5. Association of hematocrit value with cardiovascular morbidity and mortality in incident hemodialysis patients

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Serum erythropoietin in acute ischemic stroke: preliminary findings;Scientific Reports;2024-02-01

2. Prevalence and risk factors of erythropoiesis stimulating agents hyporesponsiveness in chronic hemodialysis patients attending nephrology center of Benghazi;Libyan Journal of Medical Research;2024-01-01

3. Associations of obesity and body shape with erythrocyte and reticulocyte parameters in the UK Biobank cohort;BMC Endocrine Disorders;2023-08-02

4. Is metabolic‐dysfunction‐associated fatty liver disease or advanced liver fibrosis associated with erythropoietin stimulating agent hypo‐responsiveness among patients with end‐stage kidney disease on haemodialysis?;Nephrology;2023-06-03

5. Individualization of the Dosage Regimen of Erythropoietin is Crucial in End-stage Renal Disease Patients;Saudi Journal of Kidney Diseases and Transplantation;2023